Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Disitamab Vedotin”

100 trials

Showing 20 of 100 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07591805
What this trial is testing

HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC

Who this might be right for
Upper Urinary Tract Urothelial Carcinoma
RenJi Hospital 49
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07474064
What this trial is testing

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Who this might be right for
Muscle Invasive Bladder Cancer (MIBC)
chenxu 146
Large-scale testing (Phase 3)Looking for participantsNCT07315750
What this trial is testing

Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Who this might be right for
Gastric Carcinoma
RemeGen Co., Ltd. 555
Testing effectiveness (Phase 2)Looking for participantsNCT06178159
What this trial is testing

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 40
Early research (Phase 1)UnknownNCT05514158
What this trial is testing

To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)

Who this might be right for
Gastric Cancer
RemeGen Co., Ltd. 24
Testing effectiveness (Phase 2)UnknownNCT05726175
What this trial is testing

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Who this might be right for
Breast Cancer
West China Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT06389006
What this trial is testing

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 79
Post-approval studies (Phase 4)UnknownNCT05661357
What this trial is testing

Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression

Who this might be right for
HER2Colorectal Cancer
Zhongnan Hospital 51
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06630871
What this trial is testing

A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.

Who this might be right for
NMIBC
Fujian Medical University Union Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT07446452
What this trial is testing

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Who this might be right for
HER2-low Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 37
Testing effectiveness (Phase 2)Looking for participantsNCT06749860
What this trial is testing

Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression

Who this might be right for
Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 58
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06385873
What this trial is testing

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Who this might be right for
Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06957561
What this trial is testing

Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Who this might be right for
Bladder CancerMuscle-invasive Bladder Cancer
Sun Yat-sen University 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05586061
What this trial is testing

First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer

Who this might be right for
HER2-positive Gastric Cancer
Qilu Hospital of Shandong University 55
Testing effectiveness (Phase 2)UnknownNCT05113459
What this trial is testing

Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer（RC48-C018）

Who this might be right for
Gastric Cancer
Guoxin Li 40
Testing effectiveness (Phase 2)Looking for participantsNCT06734182
What this trial is testing

Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Guangdong Provincial People's Hospital 25
Not applicableLooking for participantsNCT05851677
What this trial is testing

Disitamab Vedotin (RC48-ADC) in Breast Cancer

Who this might be right for
Breast Cancer
RenJi Hospital 45
Testing effectiveness (Phase 2)UnknownNCT05627414
What this trial is testing

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Who this might be right for
Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT07717242
What this trial is testing

Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer

Who this might be right for
Bladder Urothelial CarcinomaBladder Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 80
Large-scale testing (Phase 3)Looking for participantsNCT05904964
What this trial is testing

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

Who this might be right for
HR Positive/HER2 Low Expression Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 288
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation